Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Company News

Deal streak continues for Alexion as Achillion’s story hits $930M high note

October 17, 2019 12:22 AM UTC
Updated on Oct 17, 2019 at 12:26 AM UTC

Alexion’s proposed takeout of Achillion would complete a 21-year journey that saw the latter evolve from an antiviral play into a complement pathway company. For Alexion, it represents the next step in its quest to build its pipeline beyond Soliris.

The takeout, announced Wednesday, would see Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) acquire Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) for $6.30 per share in cash, and give Alexion two complement inhibitors to supplement its leading position in paroxysmal nocturnal hemoglobinuria...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article